Five things for pharma marketers to know: Friday, April 14, 2017

Five things for pharma marketers to know: Friday, April 14, 2017

Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug

SPONSORED: Rebooting your approach to HUB services

SPONSORED: Rebooting your approach to HUB services

A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

MM&M names winners of Young Jurists program

MM&M names winners of Young Jurists program

Meet Medela's Katie Busse, Intouch Solutions' Andrew Grojean, Heartbeat's Meghan Kate, Fingerpaint's Travis Rooke, and Havas Life Metro's Dan Sorine.

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Off-label legal settlements do little to change prescribing patterns

Off-label legal settlements do little to change prescribing patterns

An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.

Large teaching hospitals more prone to breaches

Large teaching hospitals more prone to breaches

These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Excedrin acts fast to ease Mets fan's headache

Excedrin acts fast to ease Mets fan's headache

Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Bayer, Eli Lilly, GlaxoSmithKline, and Sanofi have suspended advertising on the show, according to news reports.

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Several of the top-spending brands have never hired more than one female or non-white marketing boss, and some never have.

Five things for pharma marketers to know: Wednesday, April 5, 2017

Five things for pharma marketers to know: Wednesday, April 5, 2017

GSK pulls ads from "The O'Reilly Factor"; the FDA approves drug for Huntington's disease patients; lawmakers may remove pre-existing conditions requirement

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Five things for pharma marketers to know: Monday, April 3, 2017

Five things for pharma marketers to know: Monday, April 3, 2017

Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall

Humana navigates health insurance ups and downs

Humana navigates health insurance ups and downs

Tom Noland says protecting and enhancing Humana's reputation comes down to three things: corporate volunteerism, good media relations, and content creation.

Five things for pharma marketers to know: Friday, March 31, 2017

Five things for pharma marketers to know: Friday, March 31, 2017

Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics

Cannes Lions announces pharma, health and wellness juries

Cannes Lions announces pharma, health and wellness juries

This year's festival will be held June 17 and 18.

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Drummy passes the torch at Heartbeat, moves to chairman role

Drummy passes the torch at Heartbeat, moves to chairman role

Agency vets Nadine Leonard and James Talerico to co-lead Publicis-owned shop.

Five things for pharma marketers to know: Wednesday, March 29, 2017

Five things for pharma marketers to know: Wednesday, March 29, 2017

A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year

Senate committee launches investigation into opioid marketing

Senate committee launches investigation into opioid marketing

The committee is seeking information about the companies' sales and marketing strategies.

Five things for pharma marketers to know: Tuesday, March 28, 2017

Five things for pharma marketers to know: Tuesday, March 28, 2017

Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results

Veeva and QuintilesIMS tussle over customer reference data

Veeva and QuintilesIMS tussle over customer reference data

Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.

Five things for pharma marketers to know: Monday, March 27, 2017

Five things for pharma marketers to know: Monday, March 27, 2017

Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Five things for pharma marketers to know: Thursday, March 23, 2017

Five things for pharma marketers to know: Thursday, March 23, 2017

AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche

Healthgrades' Eric Jensen on providing quality of life

Healthgrades' Eric Jensen on providing quality of life

Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.

The 'i's have it for eye-care brand Xiidra

The 'i's have it for eye-care brand Xiidra

The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Low-T DTC ads linked with more testing — and more prescriptions

Low-T DTC ads linked with more testing — and more prescriptions

Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

MM&M Startup Showdown connects startups with biopharma execs

MM&M Startup Showdown connects startups with biopharma execs

This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

New healthcare bill to negatively affect drugmakers: Moody's

New healthcare bill to negatively affect drugmakers: Moody's

Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Five things for pharma marketers to know: Thursday, March 16, 2017

Five things for pharma marketers to know: Thursday, March 16, 2017

Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices

Industry groups petition the FDA over off-label rule

Industry groups petition the FDA over off-label rule

PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.

Common joins Allergan campaign against vision loss

Common joins Allergan campaign against vision loss

Allergan's national vision-loss-prevention campaign, See America, has brought on rapper Common as a celebrity spokesman.

Five things for pharma marketers to know: Wednesday, March 15, 2017

Five things for pharma marketers to know: Wednesday, March 15, 2017

The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits

Digital IDs become focus as drugmakers seek to track doctors' behavior online

Digital IDs become focus as drugmakers seek to track doctors' behavior online

Organizations are focusing on better ways to verify HCPs' digital identities.

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Monday at SXSW: That's a wrap

Monday at SXSW: That's a wrap

SXSW's health track finally got a seat at the big-kids table.

Five things for pharma marketers to know: Monday, March 13, 2017

Five things for pharma marketers to know: Monday, March 13, 2017

Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS

Sunday at SXSW: Healthcare costs and cancer

Sunday at SXSW: Healthcare costs and cancer

A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.

Saturday at SXSW: Hooray for health

Saturday at SXSW: Hooray for health

The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.

MM&M conference to explore beyond-the-pill

MM&M conference to explore beyond-the-pill

The MM&M Transforming Healthcare Conference will be held May 1 in New York City.

Five things for pharma marketers to know: Friday, March 10, 2017

Five things for pharma marketers to know: Friday, March 10, 2017

Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit

Havas combines Havas Health, Havas consumer health practices into new entity

Havas combines Havas Health, Havas consumer health practices into new entity

The organization is now called Havas Health & You and continues to be led by Donna Murphy.

Five things for pharma marketers to know: Thursday, March 9, 2017

Five things for pharma marketers to know: Thursday, March 9, 2017

Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled

Klara's Simon Lorenz on breaking away from the physician lifestyle

Klara's Simon Lorenz on breaking away from the physician lifestyle

He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.

MM&M's 2017 Agency A-to-Z survey is open

MM&M's 2017 Agency A-to-Z survey is open

The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Doctors seek more transparency from drugmakers: ePharma panel

Doctors seek more transparency from drugmakers: ePharma panel

Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies

Amgen launches new Repatha DTC ad

Amgen launches new Repatha DTC ad

The new spot for its cholesterol-lowering injection debuted last week.

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Pfizer and Bristol-Myers Squibb were the top spenders last year.

Five things for pharma marketers to know: Friday, March 3, 2017

Five things for pharma marketers to know: Friday, March 3, 2017

Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

2017 Healthcare Marketers Trend Report: All the data in one place

2017 Healthcare Marketers Trend Report: All the data in one place

The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Five things for pharma marketers to know: Wednesday, March 1, 2017

Five things for pharma marketers to know: Wednesday, March 1, 2017

Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported

MM&M's top 5 stories in February 2017

MM&M's top 5 stories in February 2017

WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant added 250 primary care sales reps to promote its Salix portfolio.

Havas Health, Vencore form JV focused on rare diseases

Havas Health, Vencore form JV focused on rare diseases

The joint venture pairs a communication powerhouse with a provider of defense-department-grade predictive analytics.

Five things for pharma marketers to know: Tuesday, February 28, 2017

Five things for pharma marketers to know: Tuesday, February 28, 2017

J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking

Cigna partners with Microsoft HoloLens on biometric game

Cigna partners with Microsoft HoloLens on biometric game

The health insurer partnered with Microsoft to use VR and AR technology to gather biometric data.

Five things for pharma marketers to know: Monday, February 27, 2017

Five things for pharma marketers to know: Monday, February 27, 2017

Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA

Publicis Health formalizes new name, promotes 3 execs

Publicis Health formalizes new name, promotes 3 execs

The network was previously called Publicis Healthcare Communications Group.

Five things for pharma marketers to know: Friday, February 24, 2017

Five things for pharma marketers to know: Friday, February 24, 2017

PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug

MAHF honors Abbate and Lazur, Future Famers

MAHF honors Abbate and Lazur, Future Famers

The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Almost one-third of programmatic ads violate IAB guidelines, study finds

Almost one-third of programmatic ads violate IAB guidelines, study finds

The report identifies four major issues of the 28% that were found to abuse IAB's standards.

Five things for pharma marketers to know: Wednesday, February 22, 2017

Five things for pharma marketers to know: Wednesday, February 22, 2017

Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead

Deloitte taps Havas Lynx's Mickelberg as MD

Deloitte taps Havas Lynx's Mickelberg as MD

Dennis Urbaniak has also been named chief digital officer at Havas Lynx.

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

How VAYA Pharma used Facebook ads for its ADHD campaign

How VAYA Pharma used Facebook ads for its ADHD campaign

The campaign would require a two-fold approach: Facebook link ads and Facebook Audience Network.

WebMD considers sale or merger

WebMD considers sale or merger

Drugmakers are becoming much more cautious with their budgets, WebMD executives said.

Five things for pharma marketers to know: Friday, February 17, 2017

Five things for pharma marketers to know: Friday, February 17, 2017

Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March

Five things for pharma marketers to know: Thursday, February 16, 2017

Five things for pharma marketers to know: Thursday, February 16, 2017

The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

Novo Nordisk appoints new CEO, and more people moves for you to know about

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Tuesday, February 14, 2017

Five things for pharma marketers to know: Tuesday, February 14, 2017

More older Americans are taking at least three psychiatric drugs; Marathon to pause launch of Emflaza; Aetna and Humana call off deal

Bayer creates 'everyday hero' campaign for aspirin

Bayer creates 'everyday hero' campaign for aspirin

The drugmaker worked with creative agency BBDO and PR firm Marina Maher Communications to develop the campaign.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

J2 Global considers divesting parts of Everyday Health

J2 Global considers divesting parts of Everyday Health

The company acquired Everyday Health in December.

Intouch Solutions and Healthware form joint venture

Intouch Solutions and Healthware form joint venture

The new venture aims to provide clients with global reach.

Five things for pharma marketers to know: Friday, February 10, 2016

Five things for pharma marketers to know: Friday, February 10, 2016

Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS

Five things for pharma marketers to know: Thursday, February 9, 2017

Five things for pharma marketers to know: Thursday, February 9, 2017

Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

GSK prepares for Advair competition

GSK prepares for Advair competition

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

The drugmaker is planning a commercial boost for its HIV-prevention drug.

OPINION

Newsletters